Ultragenyx Pharmaceutical

Nasdaq RARE · Novato, CA

Works in Dermatology · Genetic & rare · GI & liver · Hematology · Metabolic & endocrine · Musculoskeletal · Neurology · Psychiatry · Renal & urogenital · Women's health

Ultragenyx Pharmaceutical is a clinical trial sponsor based in Novato, CA, listed as Nasdaq RARE. It has 16 active clinical trials with 1,758 planned participants, across 10 therapeutic areas. Since 2021 it has completed 15 trials and stopped 14 early.

Trial track record · since 2021

16Active trials1,758 planned participants
15Completed11 with results posted
14Stopped early48% of finished trials

Financials · Nasdaq RARE

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Pipeline · 16 active trials

StageTrialStatus

On the market

2 approved drug applications with a product on the market.

Questions about Ultragenyx Pharmaceutical

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-11-04.

Approve Suite is not affiliated with Ultragenyx Pharmaceutical.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.